Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Conditions: Fluid Therapy; Water Electrolyte Imbalance; Acid Base Imbalance
Interventions: Drug: Crystalloid; Drug: Colloid
Sponsor: University of Nottingham
Not yet recruiting - verified March 2010
Conditions: Type 2 Diabetes; Hypogonadism
Intervention: Drug: Testosterone
Sponsor: Tameside Hospital NHS Foundation Trust
Not yet recruiting - verified November 2008
Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: NN9925 (oral); Drug: NN9925 (i.v.); Drug: placebo; Drug: NN9925 (oral); Drug: placebo
Sponsor: Novo Nordisk
Not yet recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: AZD5069
Sponsors: AstraZeneca; Quintiles
Recruiting - verified March 2010
Condition: Coronary Artery Disease
Intervention: Device: Radi pressure wire (pressure wire assessment)
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified October 2009
Condition: Neuromuscular Disease
Interventions: Drug: A0001 (alpha-tocopherolquinone); Drug: Placebo
Sponsor: Penwest Pharmaceuticals Co.
Recruiting - verified February 2010
Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
Condition: HIV Infections
Interventions: Biological: HIV-v (Low Dose); Biological: HIV-v (High Dose); Biological: HIV-v (Control)
Sponsor: PepTcell Limited
Recruiting - verified February 2010
Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Not yet recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: Matching placebo; Drug: Otelixizumab
Sponsor: GlaxoSmithKline
Not yet recruiting - verified February 2010
Condition: Type 1 Diabetes
Interventions: Other: Closed-loop insulin delivery; Other: Standard insulin pump treatment
Sponsors: University of Cambridge; Cambridge University Hospitals NHS Foundation Trust
Not yet recruiting - verified February 2010
Conditions: HIV; HIV Infections
Intervention: Drug: darunavir/ritonavir then atazanavir/ritonavir
Sponsor: St Stephens Aids Trust
Not yet recruiting - verified February 2010
Conditions: Endarterectomy, Carotid; Carotid Stenosis
Intervention: Device: OxyMask
Sponsor: Brighton and Sussex University Hospitals NHS Trust
Recruiting - verified January 2010
Conditions: Major Depressive Disorder; Healthy Volunteers
Intervention: Drug: Duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Blood Coagulation Disorders; Hemophilia A
Interventions: Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: TMC278LA
Sponsor: St Stephens Aids Trust
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Condition: Factor X Deficiency
Intervention: Biological: FACTOR X
Sponsor: Bio Products Laboratory
Not yet recruiting - verified March 2010
Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: NN9924 (oral); Drug: placebo; Drug: NN9924 (oral); Drug: placebo; Drug: NN9924 (s.c.); Drug: NN9924 (i.v.)
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Influenza A Virus, H1N1 Subtype; Influenza B Virus; Influenza, Human; Influenza, Seasonal
Intervention: Drug: zanamivir aqueous solution
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: GSK239512; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Glimepiride
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Metformin
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Hemophilia B
Intervention: Genetic: Gene Transfer
Sponsors: St. Jude Children's Research Hospital; Stanford University; Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified March 2010
Condition: Congenital FXIII Deficiency
Intervention: Drug: recombinant factor XIII
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide once weekly; Drug: insulin detemir
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2009
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsor: Cancer Research UK
Recruiting - verified August 2009
Condition: Cancer
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsor: University Hospital Birmingham
Recruiting - verified September 2009
Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells
Sponsor: Kiadis Pharma
Recruiting - verified March 2010
Condition: Haemophilia A or B With Inhibitors
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Haemophilia A; Haemophilia B; Healthy
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: placebo; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MP-513 Lowest Dose and Metformin; Drug: MP-513 Low Dose and Metformin; Drug: MP-513 Medium Dose and Metformin; Drug: MP-513 High Dose and Metformin; Drug: Placebo and Metformin
Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting - verified March 2010
Condition: Hemophilia A
Interventions: Procedure: No Drug; Procedure: No Drug; Procedure: No Drug; Procedure: No Drug; Procedure: No Drug
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Anemia; Chronic Kidney Disease
Intervention: Drug: darbepoetin alfa
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: SRT2104
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: bortezomib; Drug: Cyclophosphamide; Drug: bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: bortezomib; Drug: Dexamethasone
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib (Sprycel)
Sponsors: European Group for Blood and Marrow Transplantation; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: darunavir tablets; Drug: ritonavir capsule
Sponsors: Tibotec Pharmaceuticals, Ireland; Tibotec Pharmaceuticals
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Toxicity
Intervention: Other: Pharmacogenomic whole blood sampling
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Phenylketonuria
Interventions: Dietary Supplement: high oleic sunflower oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil
Sponsors: Ludwig-Maximilians - University of Munich; European Union
Recruiting - verified January 2010
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: PF-03526299; Drug: Placebo; Drug: Fluticasone propionate
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Hematologic Disease; Blood Coagulation Disorders
Interventions: Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 plus docetaxel; Drug: placebo plus docetaxel
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Placebo; Drug: Pemetrexed; Other: Best Supportive Care
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: ADHD
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Atomoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Conditions: Solid Tumors; Ovarian Neoplasms; Prostate Cancer
Interventions: Drug: Comparator: MK4827 (PARP inhibitor); Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Chemotherapeutic Agent Toxicity; Lymphoma; Mucositis; Neurotoxicity
Interventions: Drug: glucarpidase; Drug: leucovorin calcium; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsor: Cancer Research UK
Recruiting - verified November 2008
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Hematologic Neoplasms
Intervention: Drug: RG7112
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Conditions: Transfusional Iron Overload; Transfusional Hemosiderosis
Interventions: Drug: Deferasirox; Drug: Deferoxamine
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Lymphoma; Neutropenia; Psychosocial Effects of Cancer and Its Treatment; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: amoxicillin-clavulanate potassium; Drug: ciprofloxacin; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsor: Clatterbridge Centre for Oncology
Recruiting - verified May 2007
Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: Darbepoetin alfa
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Venous Thrombosis; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Enoxaparin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Fabry Disease; Cerebrovascular Accident
Intervention: Other: No intervention
Sponsors: University of Rostock; Shire Human Genetic Therapies, Inc.
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Conditions: Rheumatoid Arthritis; Osteoarthritis; Post-Traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis
Intervention: Device: Pinnacle Acetabular Cup System
Sponsor: DePuy International
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
All Categories ... by Medical Condition » ... Blood Disorders » ... United Kingdom 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
